Envista (NVST) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Nov, 2026Executive summary
Q3 sales were $691.5M, up 3.2% YoY; core sales grew 2.7%, with both reporting segments growing. Adjusted EBITDA rose 9% and adjusted EPS rose 25%.
Growth spanned most major geographies; China was the exception, with VBP-related orthodontics destocking and lower core sales.
FY26 adjusted earnings guidance increased, while core sales growth guidance narrowed.
GAAP results included a $428.1M non-cash foreign-currency translation gain from legal-entity dissolution; the gain was excluded from adjusted measures.
Financial highlights
Revenue was $691.5M versus $670M YoY; reported growth was 3.2% and core growth was 2.7%.
Adjusted EBITDA was $105.8M versus $97.1M; adjusted diluted EPS was $0.40 versus $0.32.
Adjusted gross margin was 56.3%, up 20 bps; adjusted EBITDA margin was 15.3%, up 80 bps.
Free cash flow was $63.5M versus $67.9M, with conversion of 97.4% of adjusted net income; Q3 included tariff refunds.
GAAP net income was $508.3M versus a $30.3M loss; adjusted net income was $65.2M versus $53.7M.
Outlook and guidance
FY26 core sales growth guidance tightened to 3.75%–4.25% from 3.5%–4.5%.
FY26 adjusted EBITDA growth guidance rose to 12.5%–14% from 11%–14%; adjusted EPS guidance rose to $1.54–$1.58 from $1.50–$1.55.
FY26 free cash flow conversion is expected to be ~100%; the adjusted tax rate is expected to be ~25.5%.
Midpoint guidance implies slightly negative Q4 core growth; excluding four fewer selling days YoY, implied growth aligns with the FY range. FX is expected to reduce Q4 reported revenue growth by ~1 point.
No significant VBP impact is expected in Q4; implementation is anticipated in H1 2027, though timing may change.
Latest events from Envista
- China VBP reforms drive short-term headwinds but position the company for future growth.NVST
2026 Global Healthcare Conference - Higher targets reflect product momentum, productivity and disciplined capital deployment.NVST
Investor Day 2026 - Strong Q2 growth, margin expansion, and raised 2026 guidance amid resilient markets.NVST
Q2 2026 - All proposals passed, directors elected, and no stockholder questions were raised.NVST
AGM 2026 - Q1 2026 saw strong sales, margin expansion, and a $300M buyback with guidance reaffirmed.NVST
Q1 2026 - Double-digit core sales, EBITDA, and EPS growth in 2025, with strong 2026 outlook.NVST
Q4 2025 - Q3 2025 delivered 9.4% core growth, 14.5% EBITDA margin, and raised full-year guidance.NVST
Q3 2025 - Q2 loss of $1.15B on impairments; sales and margins fell, but cash flow improved and Q4 growth is expected.NVST
Q2 2024 - Q4 core sales rose 2% with strong cash flow and a $250M share repurchase plan.NVST
Q4 2024